| [1] |
Yiangou A, Mollan SP, Sinclair AJ. Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms [J]. Nat Rev Neurol, 2023, 19(12): 769-785.
|
| [2] |
Amin S, Monaghan M, Forrest K, et al. Consensus recommendations for the assessment and management of idiopathic intracranial hypertension in children and young people [J]. Arch Dis Child, 2024, 109(8): 654-658.
|
| [3] |
Thaller M, Mytton J, Wakerley BR, et al. Idiopathic intracranial hypertension: Evaluation of births and fertility through the Hospital Episode Statistics dataset [J]. BJOG, 2022, 129(12): 2019-2027.
|
| [4] |
Adderley NJ, Subramanian A, Nirantharakumar K, et al. Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom [J]. JAMA Neurol, 2019, 76(9): 1088-1098.
|
| [5] |
Mollan SP, Aguiar M, Evison F, et al. The expanding burden of idiopathic intracranial hypertension [J]. Eye (Lond), 2019, 33(3): 478-485.
|
| [6] |
Mollan SP, Mitchell JL, Yiangou A, et al. Association of Amount of Weight Lost After Bariatric Surgery With Intracranial Pressure in Women With Idiopathic Intracranial Hypertension [J]. Neurology, 2022, 99(11): e1090-e1099.
|
| [7] |
Westgate CS, Botfield HF, Alimajstorovic Z, et al. Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension [J]. JCI Insight, 2021, 6(10): e145346.
|
| [8] |
Yiangou A, Mitchell JL, Vijay V, et al. Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension [J]. J Headache Pain, 2020, 21(1): 116.
|
| [9] |
Vijay V, Mollan SP, Mitchell JL, et al. Using Optical Coherence Tomography as a Surrogate of Measurements of Intracranial Pressure in Idiopathic Intracranial Hypertension [J]. JAMA Ophthalmol, 2020, 138(12): 1264-1271.
|
| [10] |
Mollan SP, Momin SNA, Khatkar PS, et al. A Neuro-Ophthalmologist's Guide to Advances in Intracranial Pressure Measurements [J]. Eye Brain, 2023, 15: 113-124.
|
| [11] |
Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management [J]. J Neurol Neurosurg Psychiatry, 2018, 89(10): 1088-1100.
|
| [12] |
Pascarella A, Manzo L, Bono F. Effect of mannitol bolus administration on cerebrospinal fluid pressure in patients with idiopathic intracranial hypertension: a pilot study. J [J]. Neurol, 2022, 269(11): 6158-6164.
|
| [13] |
Adderley NJ, Subramanian A, Perrins M, et al. Headache, Opiate Use, and Prescribing Trends in Women With Idiopathic Intracranial Hypertension: A Population-Based Matched Cohort Study [J]. Neurology, 2022, 99(18): e1968-e1978.
|
| [14] |
Gurney SP, Ramalingam S, Thomas A, et al. Exploring the current management idiopathic intracranial hypertension, and understanding the role of dural venous sinus stenting [J]. Eye Brain, 2020, 12: 1-13.
|
| [15] |
Grech O, Mitchell JL, Lyons HS, et al. Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension [J]. Eye (Lond), 2024, 38(7): 1374-1379.
|
| [16] |
Apperley L, Kumar R, Senniappan S. Idiopathic intracranial hypertension in children with obesity [J]. Acta Paediatr, 2022, 111(7): 1420-1426.
|
| [17] |
Matthews Y, Dean F, Matyka K, et al. UK surveillance of childhood idiopathic intracranial hypertension (IIH) [J]. Arch Dis Child, 2012, 97(Suppl 1): A6-A.
|
| [18] |
Stiebel-Kalish H, Serov I, Sella R, et al. Childhood overweight or obesity increases the risk of IIH recurrence fivefold [J]. Int J Obes, 2014, 38(11): 1475-1477.
|